💊
Kyinsu
insulin icodec;semaglutide
Diabetes mellitus, Typ 2
✅ Autorisiert
✅
Keine aktiven Warnungen
Dieses Arzneimittel unterliegt derzeit keinen Lieferengpässen, Sicherheitshinweisen oder Rückrufen.
Wofür es verwendet wird
Kyinsu is indicated for the treatment of adults with type 2 diabetes mellitus insufficiently controlled on basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists as an adjunct to diet and exercise in addition to oral antidiabetic medicinal products. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
⚠️ Patientensicherheit
No
Offizielle EMA-Seite
https://www.ema.europa.eu/en/medicines/human/EPAR/kyinsu